<i>MIR155HG</i> is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers

Peng, Lirong; Chen, Zhanfei; Chen, Yiyin; Wang, Xiaoqian; Tang, Nanhong

doi:10.1002/cam4.2583

Cited by 104 publications

(66 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analysis of the microenvironment has shown that immune-related pathways in uence behavior of glioma cells [36]. To evaluate the relationship between our prognostic signature and immunobiology, we evaluate its correlation with well-established immune checkpoint genes, and found that TIM3, PD1, PDL1, CTLA4, MIR155HG, and CD48, but not TIGIT [20,21,23], correlates with risk score. These ndings are to some extent consistent with those by Deng et al [14].…”

Section: Discussionmentioning

confidence: 99%

“…Differential expression of 7 established immune checkpoint genes in the low and high-risk groups was analyzed. These are, T cell immunoglobulin domain and mucin domain 3 (TIM3), programmed cell death 1 (PD1), PD1 interacts with programmed death ligand 1 (PDL1), cytotoxic T lymphocyte antigen 4 (CTLA4), T cell immunoreceptor with Ig and ITIM domains (TIGIT), long non-coding RNA MIR 155 host gene (MIR155HG), and CD48 [20][21][22][23][24] . This analysis evaluated the correlation between risk score and expression of the checkpoint genes.…”

Section: Analysis Of Correlation Between Risk Score and Expression Ofmentioning

confidence: 99%

See 1 more Smart Citation

A 1p/19q Codeletion-Associated Immune Signature for Predicting Lower Grade Glioma Prognosis

Liu

et al. 2020

Cell Mol Neurobiol

View full text Add to dashboard Cite

Background: Lower grade gliomas (LGGs) with codeletion of chromosomal arms 1p and 19q (1p/19 codeletion) has a favorable outcome. However, its overall survival (OS) varies. Here, we established an immune signature associated with 1p/19q codeletion for accurate prediction of prognosis of LGGs. Methods: We extracted RNA sequencing and corresponding clinical data of LGGs from the Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA). The CGGA and TCGA databases were dichotomized into training group and testing group. The immune-related differentially expressed genes (DEGs) associated with 1p/19q codeletion were screened using Cox proportional hazards regression analyses. A prognostic signature was established using dataset from CGGA and tested in TCGA datasets. Subsequently, we explored the correlation between the prognostic signature and immune response. Results: Thirteen immune genes associated with 1p/19q codeletion were identi ed and used to construct a prognostic signature. The 1-, 3-, 5-year survival rates of the low-risk group were approximately 97%, 89%, and 79%, while those of the high-risk group were 81%, 50% and 34%, respectively in the training group. The nomogram which comprised of age, world health organization (WHO) grade, primary or recurrent types, 1p/19q codeletion status and risk score provided accurate prediction for the survival rate of glioma. DEGs that were highly expressed in the high-risk group clustered with many immune-related pathways. Immune checkpoints including T cell immunoglobulin domain and mucin domain 3 (TIM3), programmed cell death 1 (PD1), PD1 interacting with programmed death ligand 1 (PDL1), cytotoxic T lymphocyte antigen 4 (CTLA4), T cell immunoreceptor with Ig and ITIM domains (TIGIT), long non-coding RNA MIR 155 host gene (MIR155HG), and CD48 were correlated with the risk score. VAV3 and TNFRFSF11B were found to be candidate immune checkpoints. Conclusion: The 1p/19q codeletion-associated immune signature provides accurate prediction of OS. VAV3 and TNFRFSF11B are novel immune checkpoints.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Analysis Of Correlation Between Risk Score and Expression Ofmentioning

confidence: 99%

A 1p/19q Codeletion-Associated Immune Signature for Predicting Lower Grade Glioma Prognosis

Liu

et al. 2020

Cell Mol Neurobiol

View full text Add to dashboard Cite

show abstract

“…8 Upregulation of lncRNA MIR155 host gene (MIR155HG) was associated with better overall survival (OS) or disease-free survival (DFS) in types of cancers including lung adenocarcinoma, cholangiocarcinoma and skin cutaneous melanoma. 9 In contrast, the high expression of MIR155HG was closely related to poorer OS in kidney renal clear cell carcinoma, glioblastoma multiforme, uveal melanoma and brain lower grade glioma. 9 However, the role of MIR155HG in cervical cancer remains unclear.…”

Section: Introductionmentioning

confidence: 93%

<p>MIR155HG Knockdown Inhibited the Progression of Cervical Cancer by Binding SRSF1</p>

Shen¹,

Li²,

Hu³

et al. 2020

OTT

View full text Add to dashboard Cite

Background: As the fourth most common cancer among women worldwide, cervical cancer lead to 311,000 deaths in 2018. Although the treatments have been developed, the survival rate of cervical cancer remains unsatisfactory. In this study, we aimed to identify differentially expressed lncRNAs (DEIncRNAs) between cervical cancer and adjacent normal tissues using bioinformatics analysis, and further to investigate the biological function of the DEIncRNAs in vitro and in vivo. Methods: The expression profiles from two microarray datasets (GSE6791 and GSE63514) were downloaded from GEO for analysis of DEIncRNAs between cervical cancer and adjacent normal cervical tissues. Among all DEIncRNAs, MIR155HG upregulation was identified and selected for further investigation. The effect of MIR155HG knockdown on proliferation, apoptosis and invasion in SiHa and Hela cells were evaluated. In addition, Western blot, RNA immunoprecipitation (RIP) and cell cycle assays were performed to determine the binding target of MIR155HG. Furthermore, the effect of MIR155HG knockdown on tumor growth in vivo was investigated. Results: The level of MIR155HG was found to be significantly upregulated in cervical cancer tissue compared with adjacent cervical tissue. Knockdown of MIR155HG notably inhibited the proliferation of SiHa and Hela cells by inducing apoptosis. In addition, MIR155HG knockdown decreased cell invasion. Moreover, tumor growth in xenograft was significantly inhibited by MIR155HG knockdown in vivo. Additionally, SRSF1 was identified as the binding protein of MIR155HG. Conclusion: Our findings demonstrated that MIR155HG knockdown inhibited the progression of cervical cancer by binding SRSF1, inspiring the usage of MIR155HG as a potential novel therapy target for the treatment of cervical cancer.

show abstract

“…As for circulating miRNA, they have the ability to reach various parts of the body and regulate the immune checkpoints, so measuring non-coding RNA expression in patients prior to and during treatment could determine how effective anti-PD1 therapy is. Peng and colleagues reported the strong correlation between immune checkpoints PD1 and CTLA4 with lncRNA MIR155HG, which could potentially serve as models for testing the immune inhibitors prior to clinical trial [184]. Although no other lncRNAs have been shown to have a role in evasion of immune response in lung cancer like HOTAIRM1 and MIR155HG, Denaro et al created a comprehensive list detailing the role of lncRNAs in other cancers [185].…”

Section: Role Of Non-coding Rna In Evasion Of Host Immune Systemmentioning

confidence: 99%

Non-Coding RNAs in Lung Tumor Initiation and Progression

Santos

Moreno

Zhang

2020

IJMS

View full text Add to dashboard Cite

Lung cancer is one of the deadliest forms of cancer affecting society today. Non-coding RNAs, such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), through the transcriptional, post-transcriptional, and epigenetic changes they impose, have been found to be dysregulated to affect lung cancer tumorigenesis and metastasis. This review will briefly summarize hallmarks involved in lung cancer initiation and progression. For initiation, these hallmarks include tumor initiating cells, immortalization, activation of oncogenes and inactivation of tumor suppressors. Hallmarks involved in lung cancer progression include metastasis and drug tolerance and resistance. The targeting of these hallmarks with non-coding RNAs can affect vital metabolic and cell signaling pathways, which as a result can potentially have a role in cancerous and pathological processes. By further understanding non-coding RNAs, researchers can work towards diagnoses and treatments to improve early detection and clinical response.

show abstract

MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers

Cited by 104 publications

References 47 publications

A 1p/19q Codeletion-Associated Immune Signature for Predicting Lower Grade Glioma Prognosis

A 1p/19q Codeletion-Associated Immune Signature for Predicting Lower Grade Glioma Prognosis

<p>MIR155HG Knockdown Inhibited the Progression of Cervical Cancer by Binding SRSF1</p>

Non-Coding RNAs in Lung Tumor Initiation and Progression

Contact Info

Product

Resources

About